+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

Mycobacterium Tuberculosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 215 Pages
  • September 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 5934424
Description Jump to:
The global Mycobacterium Tuberculosis Treatment Market size is likely to be valued at US$ 2.3 Bn in 2025 and is estimated to reach US$ 2.6 Bn by 2032, growing at a CAGR of 1.77% during the forecast period 2025-2032.

Market Insights

The Mycobacterium Tuberculosis Treatment Market includes a broad range of drug therapies designed to treat both latent and active tuberculosis (TB). Treatment regimens typically involve combinations of first-line and second-line drugs, administered orally, intravenously, or intramuscularly depending on disease severity and drug resistance. With TB being one of the top infectious disease killers globally, the market is strongly influenced by public health programs, government initiatives, and pharmaceutical company efforts to develop effective therapies. Growing demand for improved treatment options is expected to drive consistent, though moderate, growth in the coming years.

Market Growth Drivers

Several factors are fueling the expansion of the Mycobacterium Tuberculosis Treatment Market. The rising prevalence of TB worldwide, especially in low- and middle-income countries, is a primary driver. Global health organizations, such as WHO, are strengthening initiatives for TB eradication through funding and awareness campaigns. The emergence of multidrug-resistant TB (MDR-TB) has accelerated the need for innovative and more effective treatment solutions. In addition, investments in healthcare infrastructure, diagnostic advancements, and pharmaceutical R&D are boosting treatment availability and accessibility. Government subsidies and international funding for TB programs also provide strong support for market growth.

Market Restraints

Despite steady growth, the Mycobacterium Tuberculosis Treatment Market faces several challenges. Lengthy treatment durations, often spanning 6 to 24 months, lead to poor patient adherence and higher relapse rates. The growing incidence of MDR-TB and extensively drug-resistant TB (XDR-TB) complicates treatment regimens, increasing both costs and side effects. Limited availability of advanced drugs in underdeveloped regions, combined with healthcare disparities, slows down progress. Regulatory hurdles, generic competition, and high treatment expenses further restrict market expansion, particularly in economically constrained regions.

Market Opportunities

The Mycobacterium Tuberculosis Treatment Market presents significant opportunities in the near future. Increasing focus on shorter and more effective treatment regimens offers pharmaceutical companies opportunities to innovate and capture greater market share. The development of novel drug combinations and targeted therapies against MDR-TB is expected to strengthen the market outlook. Expanding healthcare access in emerging economies like India, China, and parts of Africa opens new avenues for growth. Strategic collaborations between governments, NGOs, and pharmaceutical firms will likely enhance drug distribution and awareness. Furthermore, advancements in digital health technologies and telemedicine could improve patient monitoring and adherence to TB treatment regimens.

Regional Outlook

  • North America: Strong focus on TB research and development, advanced healthcare infrastructure, and government initiatives to address latent TB cases drive steady growth.
  • Europe: Rising prevalence of drug-resistant TB and investments in clinical research support the market outlook.
  • Asia Pacific: Expected to dominate the market due to high TB burden in India, China, and Southeast Asia, supported by government-led programs and global funding.
  • Latin America: Moderate growth driven by improving healthcare systems and public health campaigns.
  • Middle East & Africa: Significant opportunities owing to high TB incidence rates, though market growth is constrained by limited healthcare access and economic barriers.

Leading Companies

Leading companies in the global Mycobacterium Tuberculosis Treatment Market are investing in product innovation, strategic partnerships, and affordable treatment solutions to maintain their market presence. These include:
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Endo International plc
  • Otsuka Pharmaceutical Co., Ltd.
  • STI Pharma, LLC

Market Segmentation

By Disease Type:

  • Latent TB
  • Active TB

By Treatment Type:

  • First-Line of Drugs
  • Second-Line of Drugs

By Route of Administration:

  • Oral
  • Intravenous
  • Intramuscular

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Institutional and Retail Sales

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Mycobacterium Tuberculosis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Mycobacterium Tuberculosis Treatment Market Outlook, 2019-2032
3.1. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Latent TB
3.1.1.2. Active TB
3.2. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. First-Line of Drugs
3.2.1.2. Second-Line of Drugs
3.3. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Oral
3.3.1.2. Intravenous
3.3.1.3. Intramuscular
3.4. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Online Pharmacies
3.4.1.3. Retail Pharmacies
3.4.1.4. Institutional and Retail Sales
3.5. Global Mycobacterium Tuberculosis Treatment Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Mycobacterium Tuberculosis Treatment Market Outlook, 2019-2032
4.1. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Latent TB
4.1.1.2. Active TB
4.2. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. First-Line of Drugs
4.2.1.2. Second-Line of Drugs
4.3. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Oral
4.3.1.2. Intravenous
4.3.1.3. Intramuscular
4.4. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Online Pharmacies
4.4.1.3. Retail Pharmacies
4.4.1.4. Institutional and Retail Sales
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.5.1. Key Highlights
4.5.1.1. U.S. Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
4.5.1.2. U.S. Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
4.5.1.3. U.S. Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
4.5.1.4. U.S. Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.5.1.5. Canada Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
4.5.1.6. Canada Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
4.5.1.7. Canada Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
4.5.1.8. Canada Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Mycobacterium Tuberculosis Treatment Market Outlook, 2019-2032
5.1. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Latent TB
5.1.1.2. Active TB
5.2. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. First-Line of Drugs
5.2.1.2. Second-Line of Drugs
5.3. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Intravenous
5.3.1.3. Intramuscular
5.4. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Online Pharmacies
5.4.1.3. Retail Pharmacies
5.4.1.4. Institutional and Retail Sales
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.5.1. Key Highlights
5.5.1.1. Germany Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.2. Germany Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.5.1.3. Germany Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.5.1.4. Germany Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.5. U.K. Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.6. U.K. Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.5.1.7. U.K. Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.5.1.8. U.K. Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.9. France Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.10. France Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.5.1.11. France Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.5.1.12. France Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.13. Italy Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.14. Italy Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.5.1.15. Italy Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.5.1.16. Italy Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.17. Turkey Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.18. Turkey Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.5.1.19. Turkey Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.5.1.20. Turkey Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.21. Russia Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.22. Russia Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.5.1.23. Russia Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.5.1.24. Russia Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.1.25. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.26. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
5.5.1.27. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
5.5.1.28. Rest of Europe Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, 2019-2032
6.1. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Latent TB
6.1.1.2. Active TB
6.2. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. First-Line of Drugs
6.2.1.2. Second-Line of Drugs
6.3. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Intravenous
6.3.1.3. Intramuscular
6.4. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Online Pharmacies
6.4.1.3. Retail Pharmacies
6.4.1.4. Institutional and Retail Sales
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.5.1. Key Highlights
6.5.1.1. China Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.2. China Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.5.1.3. China Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.5.1.4. China Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.5. Japan Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.6. Japan Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.5.1.7. Japan Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.5.1.8. Japan Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.9. South Korea Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.10. South Korea Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.5.1.11. South Korea Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.5.1.12. South Korea Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.13. India Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.14. India Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.5.1.15. India Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.5.1.16. India Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.17. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.18. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.5.1.19. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.5.1.20. Southeast Asia Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.1.21. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.22. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
6.5.1.23. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
6.5.1.24. Rest of Asia Pacific Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, 2019-2032
7.1. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Latent TB
7.1.1.2. Active TB
7.2. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
7.2.1.1. First-Line of Drugs
7.2.1.2. Second-Line of Drugs
7.3. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Intravenous
7.3.1.3. Intramuscular
7.4. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Online Pharmacies
7.4.1.3. Retail Pharmacies
7.4.1.4. Institutional and Retail Sales
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Brazil Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.2. Brazil Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.5.1.3. Brazil Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.5.1.4. Brazil Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.1.5. Mexico Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.6. Mexico Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.5.1.7. Mexico Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.5.1.8. Mexico Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.1.9. Argentina Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.10. Argentina Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.5.1.11. Argentina Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.5.1.12. Argentina Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.1.13. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.14. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
7.5.1.15. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
7.5.1.16. Rest of Latin America Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, 2019-2032
8.1. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Latent TB
8.1.1.2. Active TB
8.2. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. First-Line of Drugs
8.2.1.2. Second-Line of Drugs
8.3. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Intravenous
8.3.1.3. Intramuscular
8.4. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Online Pharmacies
8.4.1.3. Retail Pharmacies
8.4.1.4. Institutional and Retail Sales
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Mycobacterium Tuberculosis Treatment Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.5.1. Key Highlights
8.5.1.1. GCC Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.2. GCC Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.5.1.3. GCC Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.5.1.4. GCC Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.5. South Africa Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.6. South Africa Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.5.1.7. South Africa Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.5.1.8. South Africa Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.9. Egypt Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.10. Egypt Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.5.1.11. Egypt Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.5.1.12. Egypt Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.13. Nigeria Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.14. Nigeria Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.5.1.15. Nigeria Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.5.1.16. Nigeria Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.1.17. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.18. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Treatment Type, Value (US$ Bn), 2019-2032
8.5.1.19. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Route of Administration, Value (US$ Bn), 2019-2032
8.5.1.20. Rest of Middle East & Africa Mycobacterium Tuberculosis Treatment Market by Distribution Channel, Value (US$ Bn), 2019-2032
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Product vs Application Heatmap
9.2. Manufacturer vs Indication Heatmap
9.3. Company Market Share Analysis, 2024
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. AstraZeneca
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Johnson & Johnson Private Limited
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Eli Lilly and Company
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. F. Hoffmann-La Roche Ltd.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Mylan N.V.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Teva Pharmaceutical Industries Ltd.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Vostra Gmbh
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Sanofi
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Novartis AG
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Sun Pharmaceutical Industries Ltd.
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Aurobindo Pharma
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Lupin
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Allergan
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. Merck & Co., Inc.
9.5.14.1. Company Overview
9.5.14.2. Product Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Endo International plc
  • Otsuka Pharmaceutical Co., Ltd.
  • STI Pharma, LLC

Related Topics

Related Reports

Mycobacterium Tuberculosis Global Market Report 2025 - Product Image

Mycobacterium Tuberculosis Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Mycobacterium Tuberculosis Market - Global Forecast 2025-2030 - Product Image

Mycobacterium Tuberculosis Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Mycobacterium Tuberculosis Test Kit Market - Global Forecast 2025-2030 - Product Image

Mycobacterium Tuberculosis Test Kit Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 - Product Image

Mycobacterium Tuberculosis Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036

  • Report
  • Global
From
Tuberculosis Diagnostics Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Tuberculosis Diagnostics Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.